Moneycontrol
Get App
SENSEX NIFTY
you are here:

Thyrocare Technologies Ltd.

BSE: 539871 | NSE: THYROCARE |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE594H01019 | SECTOR: Hospitals & Medical Services

Success
Alert
Please select a Day.
Info

BSE Live

Jan 24, 16:00
547.25 -3.25 (-0.59%)
Volume
AVERAGE VOLUME
5-Day
1,428
10-Day
1,151
30-Day
1,247
706
  • Prev. Close

    550.50

  • Open Price

    550.35

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Jan 24, 15:50
548.75 -1.20 (-0.22%)
Volume
AVERAGE VOLUME
5-Day
31,212
10-Day
25,745
30-Day
21,792
8,324
  • Prev. Close

    549.95

  • Open Price

    549.60

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    548.75 (84)

ANNOUNCEMENTS ON Thyrocare Techn

  • Jan 23, 2020 19:08 Source: BSE

    Thyrocare Technologies - Board Meeting Intimation for To Consider & Approve Unaudited Standalone & Consolidated Financial Results For The Quarter/9 Months Ended 31-12-2019, Payment Of Further Interim Dividend, If Any, And Reappointment Of Dr. A. Velu

    Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, February 01, 2020, at the Corporate Office of the Company, to inter alia, consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2019, payment of further interim dividend, if any, and reappointment of Dr. A. Velumani as Managing Director & CEO, and Mr. A. Sundararaju as Executive Director & CFO. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

  • Jan 08, 2020 13:13 Source: BSE

    Thyrocare Technologies - Shareholding for the Period Ended December 31, 2019

    Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

  • Jan 06, 2020 18:46 Source: BSE

    Thyrocare Technologies - Statement Of Investor Complaints For The Quarter Ended December 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0000
    Name of the Signatory :- Ramjee Dorai
    Designation :- Company Secretary and Compliance Officer

  • Dec 31, 2019 17:19 Source: BSE

    Thyrocare Technologies - Closure of Trading Window

    This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company''s Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company''s equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with effect from January 01, 2020, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter / nine months ended December 31, 2019. We request you to please take the same on record.

  • Dec 18, 2019 18:46 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    The Company has introduced an ESOP Scheme under which 37,759 number of equity shares of face value of Rs. 10/- each have been allotted to 103 eligible employees who have exercised the Options granted to them under ESOP Scheme 2016, after getting in-principle and listing approval from both the Stock Exchanges i.e. National Stock Exchange of India Limited and BSE Limited. These shares shall rank pari passu with the existing equity shares of the Company in all respects. None of the Promoter Directors and Independent Directors was allotted shares under this scheme. With this allotment, the issued, subscribed and paid up equity capital of the Company stands increased as follows: Issued, Subscribed and Paid-up Equity Capital No. of shares Amount (Rs.) Before this issue 52,798,606 527,986,060.00 Shares now issued under ESOP 37,759 377,590.00 After this issue 52,836,365 528,363,650.00

  • Dec 13, 2019 12:37 Source: NSE

    Thyrocare Technologies Limited

    Thyrocare Technologies Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

  • Dec 13, 2019 11:02 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of Sundaram Asset Management Company Limited would be having a meeting with us at 10.30 A.M. on Saturday, December 14, 2019 at the Corporate Office of the Company. Please note that this is subject to any last minute changes.

  • Dec 09, 2019 9:56 Source: NSE

    Thyrocare Technologies Limited

    Thyrocare Technologies Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates.

  • Dec 07, 2019 10:54 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the following forthcoming Analyst Meetings: i) Meeting with the representative(s) of Banyan Capital Advisors LLP, at 11.30 A.M. on Monday, December 09, 2019. ii) Meeting with the representative(s) of PhillipCapital (India) Pvt. Ltd., at 03.30 P.M. on Wednesday, December 11, 2019. iii) Meeting with the representative(s) of Arisaig Partners, at 11.00 A.M. on Monday, December 16, 2019. iv) Meeting with the representative(s) of Spark Capital Advisors (I) Pvt. Ltd., at 11.00 A.M. on Tuesday, December 17, 2019, to be followed by a visit by them to our lab. Please note that these are subject to any last minute changes.

  • Dec 02, 2019 18:39 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the forthcoming Con-call / Analyst Meeting to be held as follows; i) Con-call with the representative(s) of Nippon India Mutual Fund, at 04.00 P.M. on Tuesday, December 03, 2019. ii) Meeting with the representative(s) of ADD Capital, at 03.30 P.M. on Wednesday, December 04, 2019, at the corporate office of the Company. Please note that these are subject to any last minute changes.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Feb 01, 2020
Remark : Quarterly Results & Interim Dividend